PRKDC Antibodies

Structure of PRKDC

PRKDC is a large protein with a molecular weight of approximately 465 kDa. There are differences in molecular weight among different species.

PRKDC contains 4128 amino acids and as a member of the PIKK family, it has a typical coiled-coil domain. Its protein structure consists of an N-terminal HEAT repeat region, a central FAT domain, a C-terminal kinase domain, and a FATC domain. These domains together form a ring-like conformation, which activates the kinase activity after binding to the Ku70/Ku80 complex. The FAT and FATC domains regulate the kinase activity through intramolecular interactions, while the HEAT repeat region mediates protein-protein interactions to ensure the correct assembly of the DNA damage repair complex.

Fig. 1 The overall structure of DNA-PKcs (PRKDC).¹

Key structural properties of PRKDC:

• Large ring structures containing an N-terminal HEAT repeat region and a C-terminal kinase domain
• The FAT and FATC domains form an intramolecular interaction interface to regulate kinase activity
• The kinase domain is responsible for phosphorylating downstream substrates and initiating DNA damage signaling
• The HEAT repeat region mediates protein-protein interactions with Ku70/Ku80 and other repair factors

Functions of PRKDC

The core function of PRKDC is to repair DNA double-strand breaks and maintain genomic stability. Additionally, it plays a significant role in the development of the immune system and the maintenance of telomeres.

PRKDC, upon recognizing DNA double-strand breaks, recruits and phosphorylates downstream repair factors, initiating the damage repair cascade reaction. Its kinase activity depends on the binding to the Ku70/Ku80 complex, forming an active full enzyme complex at the DNA damage site.

Applications of PRKDC and PRKDC Antibody in Literature

1. Chen, Yu, et al. "Role of PRKDC in cancer initiation, progression, and treatment." Cancer cell international 21.1 (2021): 563. https://doi.org/10.1186/s12935-021-02229-8

The article indicates that the PRKDC gene encodes the DNA-PKcs protein, which repairs DNA double-strand breaks through non-homologous end joining and is involved in immune tolerance and chromosome stability. DNA-PKcs affects tumor occurrence and development as well as the efficacy of radiotherapy, chemotherapy and immunotherapy, and has predictive value for treatment.

2. Miao, Zhenyan, et al. "Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375/PRKDC Axis and PD-L1 phosphorylation." Molecular Cancer 22.1 (2023): 205. https://doi.org/10.1186/s12943-023-01883-y

The article indicates that the circular RNA hsa_circ_0136666 is highly expressed in gastric cancer. It adsorbs miR-375-3p to upregulate PRKDC, promotes the phosphorylation of PD-L1 and prevents its degradation, leading to immune escape. siRNAs targeting this axis can enhance the anti-PD-L1 efficacy.

3. Saathoff, Miranda R., et al. "LMNA-PRKDC axis enhances DNA repair and promotes chemoresistance in glioblastoma." Cell Death & Disease (2025).https://doi.org/10.1038/s41419-025-08226-3

The article indicates that the LMNA-PRKDC axis in glioblastoma enhances DNA repair, leading to temozolomide resistance. The PRKDC inhibitor KU57788 can reverse the resistance and restore chemotherapy sensitivity. This axis is highly expressed in the stem cell-like tumor subpopulation, indicating poor patient survival and making it a potential therapeutic target.

4. Chen, Yu, et al. "Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors." Molecular oncology 14.9 (2020): 2096-2110. https://doi.org/10.1002/1878-0261.12739

The article indicates that PRKDC gene mutations are positively correlated with high tumor mutational burden, inflammatory microenvironment, and the efficacy of immune checkpoint inhibitors. The infiltration of CD8+ T cells and other immune cells increases in the mutated samples. The survival period of patients carrying PRKDC mutations is significantly prolonged, suggesting that it can serve as a biomarker for predicting the efficacy of immunotherapy.

5. Yang, Xiawei, et al. "Potential value of PRKDC as a therapeutic target and prognostic biomarker in pan-cancer." Medicine 101.27 (2022): e29628. https://doi.org/10.1097/MD.0000000000029628

Pan-cancer analysis revealed that PRKDC is highly expressed in tumor tissues and is associated with poor prognosis in patients. Its expression level is positively correlated with tumor immune infiltration and is involved in pathways such as cell cycle. Mutations in PRKDC are associated with better survival. This gene can serve as a therapeutic target and prognostic marker for pan-cancer.

Creative Biolabs: PRKDC Antibodies for Research

Creative Biolabs specializes in the production of high-quality PRKDC antibodies for research and industrial applications. Our portfolio includes monoclonal and polyclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom PRKDC Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our PRKDC antibodies, custom preparations, or technical support, contact us at email.